Tuesday November 13, 2025

# Type: Educational session. Title: AI for a better world
Moderation: Suzette Delaloge, France; Ghada Zakout, Netherlands

## The ethics of clinical AI systems

E. Winkler, NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, Germany

- with the advent of AI, the doctors role is changing from being the primary driver to an overseer
- AI use needs to disclosed to the patient, how? Can the patient opt-out?
- 



Link to presentation

## Patients' views on risk assessment in oncology: How are they affected by the use of AI?
D. French, The University of Manchester, Manchester, United Kingdom



Link to presentation

## Use of AI for medical decisions: Patients perception and preferences
G. Van Oortmerssen, Contact Groep GIST, Naarden, Netherlands



Link to presentation

## Legal and ethical aspects of AI use in oncology
G. Zakout, Erasmus MC - Erasmus University Rotterdam, Rotterdam, Netherlands



Link to presentation

## How to use AI to balance patient and physician perspectives
S. Delaloge, Institut Gustave Roussy, Villejuif, France



Link to presentation

# Type: Educational session. Title: Clinical trials for AI and AI for clinical trials
Moderation: Kenneth Kehl, United States of America; Sabina Berezowska, Switzerland



Link to presentation

## Clinical evidence for AI applications in breast cancer
K. Lang, Lund University, Lund, Sweden



Link to presentation

## Clinical trials with AI assistance in pathology
S. Berezowska, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland



Link to presentation

## AI for clinical trial matching, patient accrual and retention
K. Kehl, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America

- very good presentation
- need to be proactive - not reactive (e.g. request from a pharma company) -  in finding matching patients to key trials. This can and needs to be automated

Link to presentation

## Clinical trial design in the age of AI
R. Dienstmann, VHIO - Vall d'Hebron Institute of Oncology, Barcelona, Spain

- redundancy of copy-paste inclusion criteria for trials
- use cases for synthetic data

Link to presentation

## 1MO - Identification of a very low-risk subgroup in breast cancer using a combination of spatial representation and AI-derived prognostic markers.
C. Boissin, Karolinska Institutet, Stockholm, Sweden



Link to presentation

## 382MO - Enhancing Phase I Clinical Trial Selection Using Artificial Intelligence: Evaluation
of a Large Language Model Algorithm in a Dedicated Drug Development Unit
D. Silva, ULS Matosinhos - Hospital Pedro Hispano EPE - SNS, Senhora da Hora, Portugal



Link to presentation

# Type: Keynote lecture. Large language models with clinical knowledge
S. Azizi, Google DeepMind, London, United Kingdom



Link to presentation

# Type: Industry satellite symposium. AstraZeneca - Unlocking the potential of AI in precision oncology
Moderation: Frederick Klauschen, Germany



Link to presentation

## AI in oncology: Where are we now?
F. Klauschen, Charité - Universitätsmedizin Berlin, Berlin, Germany



Link to presentation

## Accelerating precision oncology: Why AI can&#8217;t wait
F.L. Lim, London, United Kingdom



Link to presentation

## Still experimental? What AI in oncology needs before going mainstream
N. Fusco, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy



Link to presentation

# Type: Educational session. Title: Human-AI interaction

Moderation: Jakob Kather, Germany; Mireia Crispin Ortuzar, United Kingdom



Link to presentation

## AI agents in tumor boards
F. Corso, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy



Link to presentation

## Explainability of multimodal AI
L. Cerdá-Alberich, Health Research Institute Hospital La Fe, Valencia, Spain



Link to presentation

## Trust in human-AI collaboration
F. Cnossen, University of Groningen, Groningen, Netherlands



Link to presentation

## Agentic AI for cancer research and trials
D. Bitterman, Brigham and Women's Hospital, Boston, United States of America



Link to presentation

## 71MO - Collaborative Human-Agent for Therapeutic Decision-Making In Cancer
Immunotherapy prediction
F. Corso, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy



Link to presentation

## 175MO - Evaluation of an AI-Enabled Platform for Cancer Prevention and Genetic Risk
Assessment in Unaffected Individuals: A Randomized Study
D. Mondal, Apollo Multi-Speciality Hospital, Kolkata, India



Link to presentation

# Type: Educational session. Title: AI to unlock the data vault

Moderation: Miriam Koopman, Netherlands; Alexander Pearson, United States of America



Link to presentation

## Foundation models for radiology
A. Chaudhari, Stanford University, Stanford, United States of America



Link to presentation

## Realtime (Hemato-)ONcology DAta (datagateway)
J. Versluis, Erasmus MC - Erasmus University Rotterdam, Rotterdam, Netherlands



Link to presentation

## Deep-diving into EHRs with AI
C. Chung, MD Anderson Cancer Center, Houston, United States of America



Link to presentation

## Open source AI for clinical data
A. Pearson, The University of Chicago, Chicago, United States of America



Link to presentation

## 176MO - What unstructured EHR data via natural language processing (NLP) adds to oncology real-world evidence: a multi-center OMOP-CDM assessment in lung cancer
C. Oeste, LynxCare Clinical Informatics N.V., Leuven, Belgium



Link to presentation

## 177MO - Multi-Center Validation of an Artificial Intelligence Electronic Health Records
Extraction Pipeline
K. Zarca, Lifen, Paris, France



Link to presentation



